Results the DHPLC find the exon 7, 9 polymorphism.
结果：变性高效液相色谱检测出7、9号外显子多态性。
Fig 3 Atlas of concordant results between DHPLC and direct sequencing. The arrows indicated the mutant peaks.
图3DHPLC与直接测序结果相符的检测图谱，箭头提示突变峰。
Screening the mutations and polymorphisms by denaturing high-performance liquid chromatography(DHPLC) and DNA sequencing Results: 1.
应用变性高效液相色谱（DHPLC）分析及直接基因测序筛查突变和多态。
CONCLUSION: We first amplified mtDNA in circulating plasma from breast cancer patients by direct PCR, checked mutation by DHPLC and confirmed results by sequencing.
结论：本实验直接用PCR扩增乳腺癌血浆核酸中线粒体基因，并用DHPLC初步筛选突变并测序证实。
Objective to detect the ABL point mutations in chronic myeloid leukemia (CML) patients treated with imatinib by denaturing high-performance liquid chromatography (DHPLC).
目的应用变性高效液相色谱(DHPLC)检测伊马替尼治疗后慢性髓性白血病(CML)患者ABL激酶区点突变。
Objective to detect the ABL point mutations in chronic myeloid leukemia (CML) patients treated with imatinib by denaturing high-performance liquid chromatography (DHPLC).
目的应用变性高效液相色谱(DHPLC)检测伊马替尼治疗后慢性髓性白血病(CML)患者ABL激酶区点突变。
应用推荐